Attached files

file filename
EX-99.1 - EX-99.1 - MEI Pharma, Inc.d948494dex991.htm





Washington D.C. 20549







Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): July 2, 2020



MEI Pharma, Inc.

(Exact name of registrant as specified in its charter)




Delaware   000-50484   51-0407811
(State or other jurisdiction of
incorporation or organization)
File Number)
  (I.R.S. Employer
Identification No.)

11455 El Camino Real, Suite 250, San Diego, CA 92130

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (858) 369-7100

3611 Valley Centre Drive, Suite 500, San Diego, California 92130

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):



Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)



Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)



Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))



Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class





Name of each exchange

on which registered

Common stock, $0.00000002 par value   MEIP   The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to section 13(a) of the Exchange Act.  ☐




Item 8.01

Other Events.

On July 2, 2020, MEI Pharma, Inc., a late-stage pharmaceutical company focused on advancing potential new therapies for cancer (the “Company”), and Helsinn Healthcare SA, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, issued a press release announcing that an interim futility analysis of the ongoing Phase 3 study of pracinostat in combination with azacitidine in patients with acute myeloid leukemia (“AML”) who are unfit to receive standard intensive chemotherapy, undertaken by the study Independent Data Monitoring Committee, has demonstrated it was unlikely to meet the primary endpoint of overall survival compared to the control group and as a result will discontinue the study. Pending further evaluation, patients currently enrolled in other pracinostat studies will continue treatment. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference.


Item 9.01

Financial Statements and Exhibits.





Exhibit 99.1    Press release of MEI Pharma, Inc., and Helsinn Healthcare SA, dated July 2, 2020 relating to the Phase 3 study of pracinostat.


Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.



/s/ Daniel P. Gold

  Daniel P. Gold
  Chief Executive Officer

Dated: July 2, 2020